Mark Chin
Partner at Avoro Capital
Mark Chin
Partner at Avoro Capital
New York City Metropolitan Area
Overview
Work Experience
Partner
2023 - Current
Biotech investment firm focused on early, mid, and late-stage private companies
Managing Director
2021 - 2023
Biotech venture capital firm focused on early, mid, and late-stage private and small-cap public companies
Investment Director
2016 - 2020
Biotech venture capital firm focused on early, mid, and late-stage private companies Notable deals include: VelosBio (acquired by Merck for $2.75b): Co-led Series A financing Imara (IMRA): Co-led Series B financing Harpoon Therapeutics (HARP): Co-led Series B financing Aura Biosceinces: Co-led Series C financing
Principal
2012 - 2016
Life sciences investment firm that focuses on venture growth investments in drug development and medical technology
Consultant
2011 - 2012
Healthcare practice with an emphasis in early-stage biotechnology and pharmaceuticals
Corporate Development
2010 - 2010
Market Planning
2009 - 2009
BioOncology Pipeline Market Planning for T-DM1
Manager
2006 - 2008
Life sciences strategy consulting firm focused on pharmaceutical, biotechnology, and private equity clients
Senior Business Analyst
2004 - 2006
Financial services strategy consulting firm focused on banks, insurers, and private equity clients
Analyst
2004 - 2004